MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Accounts Receivables 2011-2026 | XGN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.9 M | 7.84 M | 6.55 M | 6.08 M | 9.65 M | 8.91 M | 5.72 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.9 M | 5.72 M | 7.94 M |
Quarterly Accounts Receivables Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.1 M | 14.3 M | 14.7 M | 7.84 M | 9.39 M | 11.7 M | 10.9 M | 6.55 M | 17 M | 16.2 M | 9.3 M | 6.08 M | 10.6 M | 8.72 M | 10.9 M | 9.65 M | 9.21 M | 8.78 M | 8.22 M | 8.91 M | 8.91 M | 8.91 M | 8.91 M | 5.72 M | 5.72 M | 5.72 M | 5.72 M | 5.95 M | 5.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17 M | 5.72 M | 9.37 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Agilent Technologies
A
|
1.17 B | $ 114.87 | -0.65 % | $ 34.9 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
190 K | $ 1.63 | -1.21 % | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 24.7 | -1.12 % | $ 686 M | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 21.91 | 0.27 % | $ 1.17 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 15.3 | -1.92 % | $ 463 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M |  China |
 |
Charles River Laboratories International
CRL
|
709 M | $ 166.79 | -2.59 % | $ 8.27 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
138 M | $ 83.09 | -6.11 % | $ 10.4 B | USA |
 |
Illumina
ILMN
|
735 M | $ 126.92 | -1.24 % | $ 20.2 B | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
5.65 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
402 M | $ 409.65 | -2.78 % | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K |  Israel |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 102.49 | -0.7 % | $ 8.45 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 259.57 | -1.47 % | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
159 M | $ 9.02 | 4.76 % | $ 1.16 B | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.34 | -1.16 % | $ 2.03 B | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.84 | 0.21 % | $ 448 M | USA |
 |
Natera
NTRA
|
244 M | $ 200.17 | -2.06 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 195.05 | -0.8 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
29.3 K | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
30 K | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
783 M | - | -0.91 % | $ 14.7 B | USA |
 |
Precipio
PRPO
|
1.98 M | $ 31.75 | 3.42 % | $ 51 M | USA |
 |
Personalis
PSNL
|
8.14 M | $ 5.5 | -7.72 % | $ 326 M | USA |
 |
Senseonics Holdings
SENS
|
205 K | $ 7.18 | -1.24 % | $ 300 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.65 | -12.64 % | $ 179 M | China |